SM
PBYI icon

Sabby Management’s Puma Biotechnology PBYI Stock Holding History

Sabby Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,177
Closed -$6.68M – 294
2016
Q4 		$6.68M Buy
2,177
+156
+8% +$6.75K 0.39% 43
2016
Q3 		$13.6M Buy
2,021
+1,563
+341% +$79K 0.51% 33
2016
Q2 		$1.36M Buy
+458
New +$14.3K 0.07% 137
2015
Q4 		– Sell
-195
Closed -$1.47M – 352
2015
Q3 		$1.47M Buy
195
+2
+1% +$189 0.06% 197
2015
Q2 		$2.25M Buy
193
+110
+133% +$19.9K 0.08% 156
2015
Q1 		$1.96M Buy
+83
New +$17.7K 0.08% 147
2014
Q4 		– Sell
-358
Closed -$8.54M – 269
2014
Q3 		$8.54M Buy
358
+283
+377% +$58.1K 0.33% 46
2014
Q2 		$495K Sell
75
-437
-85% -$31.1K 0.02% 192
2014
Q1 		$5.33M Buy
512
+320
+167% +$37.6K 0.3% 61
2013
Q4 		$1.99M Buy
+192
New +$11.3K 0.13% 87

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sabby Management's PBYI Position: Q2 2017 in Review

Sabby Management sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 10,600 shares — an estimated $394K sold.

Sabby Management first reported a position in PBYI in Q4 2014 and held it in 5 quarters. The position peaked at $3.57M in Q4 2014. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

  • Sabby Management reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 10,600 Puma Biotechnology shares in Q2 2017, an estimated $394K.
  • Sabby Management first reported a position in Puma Biotechnology in Q4 2014 and held it in 5 quarters.
  • Sabby Management's Puma Biotechnology position peaked at $3.57M in Q4 2014.
  • 154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.